Acusphere was listed on NASDAQ in 2003.
Adnexus was acquired by Bristol-Myers Squibb for $430 million in 2007.
Agensys was acquired by Astellas for up to $537 million in 2007.
Anadys Pharmaceuticals was listed on NASDAQ in 2004.
Anthera was listed on NASDAQ in 2010.
Arpida was listed on SIX Swiss Exchange in 2005.
Apreva was listed on NASDAQ in 2005 and acquired by Galenica in 2007 for $915 million.
Asthmatx was sold to Boston Scientific for up to $443 million in 2010.
Axovan was acquired by Actelion in 2004 for up to CHF252 million.
BaroFold applies its Pressure Enabled Protein Manufacturing (PreEMT™) technology to improve the tolerability, efficacy and safety of a wide variety of protein therapeutics for biopharma companies and research institutions.
Basilea was listed on SIX Swiss Exchange in 2004.
BioControl Medical develops implantable medical devices to treat disorders of the autonomic nervous system.
Biovitrum was listed on OMX Stockholm in 2006. In 2010 Biovitrum and Swedish Orphan merged forming Swedish Orphan Biovitrum.
Brahms was acquired by ThermoFischer for $470 million in 2009.
Cardion was acquired by Roche in 2003.
ChemoCentryx was listed on NASDAQ in 2012.
China Nuokang was listed on NASDAQ in 2009.
Corgentech was listed on NASDAQ in 2004.
Cytokinetics was listed on NASDAQ in 2004.
Cytos was listed on SIX Swiss Exchange in 2002.
Delenex was acquired by Cell Medica in 2016.
Ellipse Technologies was acquired by NuVasive (Nasdaq: NUVA) in 2016.
Esbatech was acquired by Alcon (Novartis) for up to $589 million.
Gemin X was acquired by Cephalon for $225 million in 2003.
Icagen was listed on NASDAQ in 2004.
Infinity Pharmaceuticals was listed on NASDAQ in 2006.
Kolltan Pharmaceuticals was acquired by Celldex for up to $235 million.
Lifeline Scientific was listed on AIM London in 2008.
Mediservice was acquired by Galenica in 2007.
Micromet was listed on NASDAQ in 2003 and subsequently acquired by Amgen for $1.16 billion.
Micrus was listed on NASDAQ in 2005 and acquired by J&J /DePuy in 2010.
Mpex was acquired by Axcan in 2011.
mtm was acquired by Roche for up to EUR19 million in 2011.
Newron was listed on SIX Swiss Exchange in 2006.
Northstar was listed on NASDAQ in 2006.
Ophthotech was listed on NASDAQ in 2013.
Panomics was acquired by Affymetrix for $73 million in 2008.
PharmaSwiss was acquired by Valeant for EUR350 million in 2009.
Precimed was acquired by GreatBatch for $125 million in 2008.
PTC was listed on NASDAQ in 2013.
Renovis was listed on NASDAQ in 2003.
Merger with Vectura Group plc (LSE: VEC) in 2016.
Sloning was acquired by Morphosys in 2010.
Syntonix was acquired by Biogen Idec for up to $120 million in 2007.
Syrrx was acquired by Takeda for $270 million in 2005.
Transform was acquired by Johnson & Johnson for $230 million in 2005.
True North Therapeutics was acquired by Bioverativ in 2017 for up to $825 million.
Xenoport was listed on NASDAQ in 2005.
Sale of position to an investor in 2009.